Biodyne
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Biodyne makes instruments and reagent kits used to detect cancer cells from body fluid samples, a diagnostic method known as liquid-based cytology (LBC).
Hospitals and clinical laboratories are the primary users, with the cervical-cancer screening market representing the largest share of its business. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, Biodyne holds patents for its proprietary blowing technology in Korea, Japan, and the United States, and supplies its products to more than a dozen countries.
Summary is AI-generated and may contain errors · figures from DART filings
Biodyne has granted Roche an exclusive licence to its blowing technology for slide-preparation instruments, with the resulting co-developed product marketed globally under the Roche brand.
Biodyne in five facts
What does Biodyne do?
Biodyne makes instruments and reagent kits used to detect cancer cells from body fluid samples, a diagnostic method known as liquid-based cytology (LBC).
Where is Biodyne listed and in which sector?
Biodyne (Korean name: 바이오다인) trades under KRX code 314930 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Biodyne?
Its market capitalisation was US$136.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Biodyne's latest annual revenue and operating profit?
For fiscal year 2025, Biodyne reported revenue of US$5.3M, operating profit of US$492.3K and net income of US$642.7K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 33.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Oct 12
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Biodyne reported consolidated results for FY2025: revenue of US$4.85M (+33.4% year on year), operating profit of US$261K (from a loss a year earlier) and net income of US$638K (+8482.5% year on year).
Earnings · Feb 2